Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,181 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06540872RecruitingPhase 2
Testing New PET/MRI Scan in Large DCIS
This study tests a new imaging method that combines a special PET scan (FAPI) with MRI to see if it can better find hidden invasive cancer in people with large areas of ductal carcinoma in situ (DCIS). It aims to improve surgical planning and avoid second surgeries.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT06541652Recruiting
Study of rare liver cancers in France
This study looks at people with rare types of liver cancer to learn more about the disease. If you have one of these rare liver cancers, your information could help doctors understand these cancers better.
AmiensAges 18 years+ - NCT06541990Recruiting
Learning program for liver cancer patients
This study tests a psychoeducational program to help patients with newly diagnosed liver cancer (HCC) learn about their condition and cope better. It aims to see if this support improves well-being.
Boston, MassachusettsAges 18 years+ - NCT06542796Recruiting
Classifying treatment effects for advanced liver cancer
This study looks at how well different treatments work for people with advanced liver cancer. It may help doctors better understand which treatments are most effective for patients like you.
Hangzhou, ZhejiangAges 18–75 - NCT06544720RecruitingPhase 1
SCG142 TCR-T cell therapy for HPV-related cancers
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Qingdao, ShandongAges 18 years+ - NCT06548867Recruiting
Study of cabozantinib in advanced kidney cancer patients
This trial looks at how well cabozantinib works in people with advanced kidney cancer that has spread. It focuses on patients who had a quick response or a long response to the drug.
Reggio EmiliaAges 18 years+ - NCT06551272RecruitingPhase 2
Gut bacteria change to help immunotherapy for liver cancer
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
BobignyAges 18 years+ - NCT06557889RecruitingPhase 2
Fewer chemo cycles with immunotherapy for head and neck cancer
This study tests whether giving fewer chemotherapy cycles combined with the immunotherapy drug pembrolizumab works as well as the standard full course of chemo plus pembrolizumab for head and neck cancer that has come back or spread. It is for people whose tumors have the PD-L1 protein.
AmiensAges 18 years+ - NCT06558227RecruitingPhase 2
ZG005 with bevacizumab vs sintilimab with bevacizumab for advanced liver cancer
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard combination (sintilimab plus bevacizumab) in people with advanced liver cancer that has spread or cannot be surgically removed. The goal is to see which combination works better and is safe.
Chengdu, SichuanAges 18–75 - NCT06559761Recruiting
Imaging to predict liver cancer aggressiveness after surgery
This study looks at whether special scans can help doctors better predict how aggressive a person's liver cancer (hepatocellular carcinoma) will be, especially right after surgery. If you are planning to have surgery to remove the tumor as your first treatment, this trial might be a good fit.
Beijing, Beijing MunicipalityAges 18–80 - NCT06563869RecruitingPhase 3
Sintilimab with chemo and growth factor before esophageal cancer surgery
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
Nanjing, JiangsuAges 18–75 - NCT06571396Recruiting
Surgery risks after immunotherapy for liver cancer
This study looks at the risks of surgery in people with liver cancer who received immunotherapy before or instead of surgery. It aims to understand how safe and effective this approach is.
Jinan, ShandongAges 18 years+ - NCT06575322Recruiting
Neoadjuvant therapy for head and neck cancer: effects on pain and mood
This trial tests whether adding immunotherapy to chemotherapy before surgery can help reduce pain, anxiety, and depression in people with head and neck cancer. The goal is to see if this approach improves quality of life during treatment.
Guanzhou, GuangdongAges 18–80 - NCT06576180Recruiting
Chemo-immunotherapy and cognition in head and neck cancer
This trial is studying whether a combination of chemotherapy (carboplatin and paclitaxel) and an immunotherapy drug (anti-PD-1) affects memory and thinking in people with head and neck cancer that can be removed with surgery. Researchers want to see if these treatments cause any cognitive changes.
Guanzhou, GuangdongAges 18–80 - NCT06576973RecruitingPhase 2
Adalimumab combo therapy for esophageal cancer before surgery
This trial tests a combination of an immunotherapy drug (adalimumab), chemotherapy, and a targeted therapy pill (apatinib) before surgery for esophageal cancer that can be removed. The goal is to see if this mix helps shrink the tumor and improve outcomes.
Hangzhou, ChinaAges 18–75 - NCT06577311RecruitingPhase 2
Light therapy for facial skin cancer (SCCis)
This study tests a light-activated treatment (photodynamic therapy) for a very early form of skin cancer on the face. It may offer an alternative to surgery.
Aventura, FloridaAges 18 years+ - NCT06581315Recruiting
Donafenib after surgery for high-risk liver cancer
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT06590246RecruitingPhase 1/Phase 2
Study of C-CAR031 for advanced GPC3-positive liver cancer
This trial tests a new type of cell therapy called C-CAR031, which is designed to target and attack liver cancer cells that have a protein called GPC3. It is for people with advanced liver cancer who have already tried other treatments and are looking for a new option.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT06598761Recruiting
Immunotherapy plus radiation after surgery for advanced UTUC
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
BeijingAges 18–80 - NCT06600165Recruiting
AI-guided microscope for basal cell skin cancer surgery
This trial tests a special microscope that uses artificial intelligence (AI) to help surgeons see exactly where skin cancer (basal cell carcinoma) ends during surgery. This could help remove all cancer cells in one go, making repeat surgeries less likely.
Munich, BavariaAges Any age - NCT07545837Recruiting
Wellness Coaching for Thyroid Cancer Survivors
This study tests whether personalized health coaching helps thyroid cancer survivors stick to their treatment plans and build healthier habits. You'll work with a coach to improve your overall wellness after thyroid cancer treatment.
Jacksonville, FloridaAges 18 years+ - NCT06601335RecruitingPhase 3
New immunotherapy combo for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
Wuhan, HubeiAges 18–75
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,181 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.